Susan M. Dymecki (born June 19, 1960) is an American geneticist and neuroscientist and director of the Biological and Biomedical Sciences PhD Program at Harvard University.

[7] During her PhD, Dymecki discovered a new gene expressed in B cells, called blk for B Lymphoid Kinase, which helps to initiate an immune response.

[5] After completing her MD-PhD training in 1992, Dymecki became a Helen Hay Whitney Fellow and John Merck Scholar at the Carnegie Institution for Science in the Department of Embryology in Washington, DC.

[8] In 1997, Dymecki filed a patent for her genetic tool, which consisted of DNA constructs that enable transgenic expression of FRT recombination sites and a Flp recombinase in non-human mammals.

[9] Her technology has aided many researchers in achieving gene insertion, deletion, and modulation as well as label cell lineages to explore developmental stages.

[11] During Dymecki's postdoctoral work at the Carnegie Institute, she pioneered the development of novel vectors that enabled targeted genetic manipulation of specific populations of mammalian cells.

[12] In a following paper in 1996, Dymecki showed that her tool not only worked in cell culture, but also in vivo in living transgenic mice to mediate gene insertion and deletion via recombination at FRT sites.

[1] By 2010, Dymecki was promoted to Full Professor in the Department of Genetics, and the following year she became the Director of the Biological and Biomedical Science PhD Program at Harvard.

[20] Following this study, Dymecki and her colleagues identified another unique serotonin population, this time characterized by Tac1-Pet1 that are also implicated in driving ventilation but differ in their projection targets and methods of sensing inhaled CO2.